These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 19102901)

  • 1. [Clinical progress of endothelin receptor antagonists therapy for pulmonary arterial hypertension(no abstract).].
    Xu XQ; Zhang JH; Jing ZC
    Zhonghua Xin Xue Guan Bing Za Zhi; 2008 Oct; 36(10):951-3. PubMed ID: 19102901
    [No Abstract]   [Full Text] [Related]  

  • 2. Endothelin-receptor antagonists in the management of pulmonary arterial hypertension: where do we stand?
    Correale M; Ferraretti A; Monaco I; Grazioli D; Di Biase M; Brunetti ND
    Vasc Health Risk Manag; 2018; 14():253-264. PubMed ID: 30323613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toward Precision Medicine in Pulmonary Arterial Hypertension.
    Austin ED; Loyd JE
    Am J Respir Crit Care Med; 2015 Dec; 192(11):1272-4. PubMed ID: 26623685
    [No Abstract]   [Full Text] [Related]  

  • 4. The importance of sex in pulmonary hypertension.
    Rich S
    Chest; 2012 Jan; 141(1):4-5. PubMed ID: 22215821
    [No Abstract]   [Full Text] [Related]  

  • 5. Macitentan for the treatment of pulmonary arterial hypertension.
    DuBrock HM; Channick RN
    Expert Rev Respir Med; 2014 Aug; 8(4):393-9. PubMed ID: 24998329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endothelin receptor antagonists in the treatment of pulmonary arterial hypertension.
    Langleben D
    Clin Chest Med; 2007 Mar; 28(1):117-25, viii. PubMed ID: 17338931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Concerning Trend for Patients With Pulmonary Hypertension in the Era of Evidence-Based Medicine.
    Maron BA; Ryan JJ
    Circulation; 2019 Apr; 139(16):1861-1864. PubMed ID: 30986105
    [No Abstract]   [Full Text] [Related]  

  • 8. Current state of endothelin receptor antagonism in hypertension and pulmonary hypertension.
    Miyagawa K; Emoto N
    Ther Adv Cardiovasc Dis; 2014 Oct; 8(5):202-16. PubMed ID: 24990369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver toxicity of sitaxentan in pulmonary arterial hypertension.
    Galiè N; Hoeper MM; Simon J; Gibbs R; Simonneau G;
    Eur Heart J; 2011 Feb; 32(4):386-7. PubMed ID: 21416695
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical pharmacology of endothelin receptor antagonists used in the treatment of pulmonary arterial hypertension.
    Chaumais MC; Guignabert C; Savale L; Jaïs X; Boucly A; Montani D; Simonneau G; Humbert M; Sitbon O
    Am J Cardiovasc Drugs; 2015 Feb; 15(1):13-26. PubMed ID: 25421754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pulmonary arterial hypertension. Therapy with the endothelin-1 receptor antagonist bosentan].
    Musch A
    Med Monatsschr Pharm; 2006 Jul; 29(7):242-5. PubMed ID: 16866076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Blockade of endothelin receptor with bosentan--a new principle of treatment in pulmonary arterial hypertension].
    Nielsen-Kudsk JE
    Ugeskr Laeger; 2003 Jul; 165(29):2891-4. PubMed ID: 12908360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perspectives on Oral Pulmonary Hypertension Therapies Recently Approved by the U.S. Food and Drug Administration.
    Burger CD
    Ann Am Thorac Soc; 2015 Jun; 12(6):959. PubMed ID: 26075561
    [No Abstract]   [Full Text] [Related]  

  • 14. Reply: Perspectives on Oral Pulmonary Hypertension Therapies Recently Approved by the U.S. Food and Drug Administration.
    Hill NS; Badesch D; Benza RL; D'Eletto TA; Farber HW; Gomberg-Maitland M; Hassoun PM; Preston I
    Ann Am Thorac Soc; 2015 Jun; 12(6):960. PubMed ID: 26075562
    [No Abstract]   [Full Text] [Related]  

  • 15. Endothelin-1 Pathway Polymorphisms and Outcomes in Pulmonary Arterial Hypertension.
    Benza RL; Gomberg-Maitland M; Demarco T; Frost AE; Torbicki A; Langleben D; Pulido T; Correa-Jaque P; Passineau MJ; Wiener HW; Tamari M; Hirota T; Kubo M; Tiwari HK
    Am J Respir Crit Care Med; 2015 Dec; 192(11):1345-54. PubMed ID: 26252367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Endothelin-receptor antagonists in therapy of pulmonary arterial hypertension].
    Ghofrani HA
    Dtsch Med Wochenschr; 2009 Aug; 134 Suppl 5():S177-8. PubMed ID: 19718611
    [No Abstract]   [Full Text] [Related]  

  • 17. Endothelin-receptor antagonists in pulmonary hypertension.
    Dupuis J
    Lancet; 2001 Oct; 358(9288):1113-4. PubMed ID: 11597660
    [No Abstract]   [Full Text] [Related]  

  • 18. Endothelin receptor antagonists for the treatment of pulmonary artery hypertension.
    Rubin LJ
    Life Sci; 2012 Oct; 91(13-14):517-21. PubMed ID: 22884806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The current pharmacotherapy of pulmonary arterial hypertension].
    Betkier-Lipińska K; Ryczek R; Cwetsch A
    Pol Merkur Lekarski; 2015 Jan; 38(223):34-8. PubMed ID: 25763586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macitentan for the treatment of pulmonary arterial hypertension.
    Kholdani CA; Fares WH; Trow TK
    Vasc Health Risk Manag; 2014; 10():665-73. PubMed ID: 25473292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.